Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcript… Read more
Anbio Biotechnology Class A Ordinary Shares (NNNN) - Total Liabilities
Latest total liabilities as of June 2025: $153.92K USD
Based on the latest financial reports, Anbio Biotechnology Class A Ordinary Shares (NNNN) has total liabilities worth $153.92K USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Anbio Biotechnology Class A Ordinary Shares - Total Liabilities Trend (2021–2024)
This chart illustrates how Anbio Biotechnology Class A Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Anbio Biotechnology Class A Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of Anbio Biotechnology Class A Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Partners Value Investments LP
V:PVF-UN
|
Canada | CA$1.36 Billion |
|
Rianlon Corp
SHE:300596
|
China | CN¥5.05 Billion |
|
Sun Country Airlines Holdings Inc
NASDAQ:SNCY
|
USA | $1.06 Billion |
|
Compania de Transporte de Energia Electrica en Alta Tension Transener SA
BA:TRAN
|
Argentina | AR$280.60 Billion |
|
Magic Software Enterprises Ltd
NASDAQ:MGIC
|
USA | $258.98 Million |
|
Sichuan Swellfun Co Ltd
SHG:600779
|
China | CN¥3.25 Billion |
|
Jeju Semiconductor Corp
KQ:080220
|
Korea | ₩95.37 Billion |
|
Samhaellsbyggnadsbolaget i Norden AB Series D
ST:SBB-D
|
Sweden | Skr52.19 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down Anbio Biotechnology Class A Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 211.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.00 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Anbio Biotechnology Class A Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Anbio Biotechnology Class A Ordinary Shares (2021–2024)
The table below shows the annual total liabilities of Anbio Biotechnology Class A Ordinary Shares from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.73 Million | +74.23% |
| 2023-12-31 | $993.06K | -29.63% |
| 2022-12-31 | $1.41 Million | -40.70% |
| 2021-12-31 | $2.38 Million | -- |